{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T09:04:47Z","timestamp":1749805487370},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13063-016-1583-y","type":"journal-article","created":{"date-parts":[[2016,9,21]],"date-time":"2016-09-21T08:53:00Z","timestamp":1474447980000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lapatinib-capecitabine versus capecitabine alone as radiosensitizers in RAS wild-type resectable rectal cancer, an adaptive randomized phase II trial (LaRRC trial): study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"17","author":[{"given":"Nuno","family":"Sousa","sequence":"first","affiliation":[]},{"given":"Olga","family":"Sousa","sequence":"additional","affiliation":[]},{"given":"L\u00facio Lara","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[]},{"given":"Manuel R.","family":"Teixeira","sequence":"additional","affiliation":[]},{"given":"M\u00e1rio","family":"Dinis-Ribeiro","sequence":"additional","affiliation":[]},{"given":"Armando","family":"Teixeira-Pinto","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,9,21]]},"reference":[{"issue":"3","key":"1583_CR1","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/annonc\/mdl498","volume":"18","author":"J Ferlay","year":"2007","unstructured":"Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581\u201392. doi: 10.1093\/annonc\/mdl498 .","journal-title":"Ann Oncol"},{"key":"1583_CR2","volume-title":"Cancer incidence in five continents, vol. IX. IARC scientific publications","year":"2009","unstructured":"Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P, editors. Cancer incidence in five continents, vol. IX. IARC scientific publications. Lyon: IARC (International Agency for Research on Cancer); 2009."},{"issue":"8","key":"1583_CR3","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/S1470-2045(08)70179-7","volume":"9","author":"MP Coleman","year":"2008","unstructured":"Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008;9(8):730\u201356. doi: 10.1016\/S1470-2045(08)70179-7 .","journal-title":"Lancet Oncol"},{"issue":"9","key":"1583_CR4","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1046\/j.1365-2168.2002.02196.x","volume":"89","author":"E Kapiteijn","year":"2002","unstructured":"Kapiteijn E, Putter H, van de Velde CJ. Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. Br J Surg. 2002;89(9):1142\u20139. doi: 10.1046\/j.1365-2168.2002.02196.x .","journal-title":"Br J Surg"},{"key":"1583_CR5","doi-asserted-by":"publisher","first-page":"CD002102","DOI":"10.1002\/14651858.CD002102.pub2","volume":"2","author":"RK Wong","year":"2007","unstructured":"Wong RK, Tandan V, De Silva S, Figueredo A. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev. 2007;2:CD002102. doi: 10.1002\/14651858.CD002102.pub2 .","journal-title":"Cochrane Database Syst Rev"},{"key":"1583_CR6","doi-asserted-by":"publisher","first-page":"CD006041","DOI":"10.1002\/14651858.CD006041.pub2","volume":"1","author":"WP Ceelen","year":"2009","unstructured":"Ceelen WP, Van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev. 2009;1:CD006041. doi: 10.1002\/14651858.CD006041.pub2 .","journal-title":"Cochrane Database Syst Rev"},{"issue":"28","key":"1583_CR7","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.1200\/JCO.2007.11.9685","volume":"25","author":"L Collette","year":"2007","unstructured":"Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol. 2007;25(28):4379\u201386. doi: 10.1200\/JCO.2007.11.9685 .","journal-title":"J Clin Oncol"},{"issue":"11","key":"1583_CR8","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa060829","volume":"355","author":"JF Bosset","year":"2006","unstructured":"Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114\u201323. doi: 10.1056\/NEJMoa060829 .","journal-title":"N Engl J Med"},{"issue":"28","key":"1583_CR9","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.1200\/JCO.2006.06.7629","volume":"24","author":"JP Gerard","year":"2006","unstructured":"Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620\u20135. doi: 10.1200\/JCO.2006.06.7629 .","journal-title":"J Clin Oncol"},{"key":"1583_CR10","unstructured":"Capecitabine, summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000316\/WC500058151.pdf ."},{"issue":"3","key":"1583_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/COC.0b013e318161dbd3","volume":"31","author":"A Ballonoff","year":"2008","unstructured":"Ballonoff A, Kavanagh B, McCarter M, Kane M, Pearlman N, Nash R, et al. Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. Am J Clin Oncol. 2008;31(3):264\u201370. doi: 10.1097\/COC.0b013e318161dbd3 .","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"1583_CR12","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/annonc\/mdj041","volume":"17","author":"A Paoli De","year":"2006","unstructured":"De Paoli A, Chiara S, Luppi G, Friso ML, Beretta GD, Del Prete S, et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol. 2006;17(2):246\u201351. doi: 10.1093\/annonc\/mdj041 .","journal-title":"Ann Oncol"},{"issue":"9","key":"1583_CR13","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s00066-008-1751-4","volume":"184","author":"J Dunst","year":"2008","unstructured":"Dunst J, Debus J, Rudat V, Wulf J, Budach W, Hoelscher T, et al. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial. Strahlenther Onkol. 2008;184(9):450\u20136. doi: 10.1007\/s00066-008-1751-4 .","journal-title":"Strahlenther Onkol"},{"issue":"3","key":"1583_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/COC.0b013e3181a650e8","volume":"33","author":"W Marsh Rde","year":"2010","unstructured":"Marsh Rde W, George TJ, Siddiqui T, Mendenhall WM, Zlotecki RA, Grobmyer S, et al. A phase II trial of neoadjuvant capecitabine combined with hyperfractionated accelerated radiation therapy in locally advanced rectal cancer. Am J Clin Oncol. 2010;33(3):251\u20136. doi: 10.1097\/COC.0b013e3181a650e8 .","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"1583_CR15","first-page":"693","volume":"47","author":"V Velenik","year":"2006","unstructured":"Velenik V, Anderluh F, Oblak I, Strojan P, Zakotnik B. Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial. Croat Med J. 2006;47(5):693\u2013700.","journal-title":"Croat Med J"},{"key":"1583_CR16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000327010","volume":"34","author":"RD Hofheinz","year":"2011","unstructured":"Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo-)adjuvant chemo-radiotherapy (CRT) for locally advanced rectal cancer (LARC): long-term results of a randomized, phase III trial. Onkologie. 2011;34:199.","journal-title":"Onkologie"},{"issue":"3","key":"1583_CR17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","volume":"19","author":"DS Salomon","year":"1995","unstructured":"Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19(3):183\u2013232.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1583_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1059\/0003-4819-154-1-201101040-00006","volume":"154","author":"IJ Dahabreh","year":"2011","unstructured":"Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med. 2011;154(1):37\u201349. doi: 10.1059\/0003-4819-154-1-201101040-00006 .","journal-title":"Ann Intern Med"},{"issue":"31","key":"1583_CR19","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697\u2013705. doi: 10.1200\/JCO.2009.27.4860 .","journal-title":"J Clin Oncol"},{"issue":"17","key":"1583_CR20","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","volume":"359","author":"CS Karapetis","year":"2008","unstructured":"Karapetis CS, Khambata-Ford S, Jonker DJ, O\u2019Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757\u201365. doi: 10.1056\/NEJMoa0804385 .","journal-title":"N Engl J Med"},{"issue":"31","key":"1583_CR21","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(31):4706\u201313. doi: 10.1200\/JCO.2009.27.6055 .","journal-title":"J Clin Oncol"},{"issue":"14","key":"1583_CR22","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Cutsem Van","year":"2009","unstructured":"Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408\u201317. doi: 10.1056\/NEJMoa0805019 .","journal-title":"N Engl J Med"},{"issue":"7","key":"1583_CR23","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","volume":"33","author":"E Cutsem Van","year":"2015","unstructured":"Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezinek I, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015;33(7):692\u2013700. doi: 10.1200\/JCO.2014.59.4812 .","journal-title":"J Clin Oncol"},{"issue":"18","key":"1583_CR24","doi-asserted-by":"publisher","first-page":"5935","DOI":"10.1158\/1078-0432.ccr-11-0370","volume":"17","author":"KM Quesnelle","year":"2011","unstructured":"Quesnelle KM, Grandis JR. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res. 2011;17(18):5935\u201344. doi: 10.1158\/1078-0432.ccr-11-0370 .","journal-title":"Clin Cancer Res"},{"issue":"99","key":"1583_CR25","doi-asserted-by":"publisher","first-page":"99ra86","DOI":"10.1126\/scitranslmed.3002442","volume":"3","author":"K Yonesaka","year":"2011","unstructured":"Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011;3(99):99ra86. doi: 10.1126\/scitranslmed.3002442 .","journal-title":"Sci Transl Med"},{"issue":"15","key":"1583_CR26","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.ejca.2008.06.029","volume":"44","author":"N Magne","year":"2008","unstructured":"Magne N, Chargari C, Castadot P, Ghalibafian M, Soria JC, Haie-Meder C, et al. The efficacy and toxicity of EGFR in the settings of radiotherapy: focus on published clinical trials. Eur J Cancer. 2008;44(15):2133\u201343. doi: 10.1016\/j.ejca.2008.06.029 .","journal-title":"Eur J Cancer"},{"issue":"6","key":"1583_CR27","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.canrad.2004.09.002","volume":"8","author":"G Milano","year":"2004","unstructured":"Milano G, Magne N. Anti-EGFR and radiotherapy. Cancer Radiother. 2004;8(6):380\u20132. doi: 10.1016\/j.canrad.2004.09.002 .","journal-title":"Cancer Radiother"},{"issue":"4","key":"1583_CR28","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1200\/JCO.2005.04.1749","volume":"24","author":"BG Czito","year":"2006","unstructured":"Czito BG, Willett CG, Bendell JC, Morse MA, Tyler DS, Fernando NH, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol. 2006;24(4):656\u201362. doi: 10.1200\/JCO.2005.04.1749 .","journal-title":"J Clin Oncol"},{"issue":"6","key":"1583_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00066-009-1936-5","volume":"185","author":"F Marquardt","year":"2009","unstructured":"Marquardt F, Rodel F, Capalbo G, Weiss C, Rodel C. Molecular targeted treatment and radiation therapy for rectal cancer. Strahlenther Onkol. 2009;185(6):371\u20138. doi: 10.1007\/s00066-009-1936-5 .","journal-title":"Strahlenther Onkol"},{"issue":"3","key":"1583_CR30","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ijrobp.2008.01.046","volume":"72","author":"V Valentini","year":"2008","unstructured":"Valentini V, De Paoli A, Gambacorta MA, Mantini G, Ratto C, Vecchio FM, et al. Infusional 5-fluorouracil and ZD1839 (gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II trial (1839IL\/0092). Int J Radiat Oncol Biol Phys. 2008;72(3):644\u20139. doi: 10.1016\/j.ijrobp.2008.01.046 .","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"1583_CR31","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s00280-008-0820-9","volume":"63","author":"E Giannopoulou","year":"2009","unstructured":"Giannopoulou E, Antonacopoulou A, Floratou K, Papavassiliou AG, Kalofonos HP. Dual targeting of EGFR and HER-2 in colon cancer cell lines. Cancer Chemother Pharmacol. 2009;63(6):973\u201381. doi: 10.1007\/s00280-008-0820-9 .","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1583_CR32","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1158\/0008-5472.CAN-05-2506","volume":"66","author":"Y Zhou","year":"2006","unstructured":"Zhou Y, Li S, Hu YP, Wang J, Hauser J, Conway AN, et al. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res. 2006;66(1):404\u201311. doi: 10.1158\/0008-5472.CAN-05-2506 .","journal-title":"Cancer Res"},{"issue":"3","key":"1583_CR33","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.radonc.2009.09.006","volume":"93","author":"MJ Sambade","year":"2009","unstructured":"Sambade MJ, Camp JT, Kimple RJ, Sartor CI, Shields JM. Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf\u2009>\u2009MEK\u2009>\u2009ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK. Radiother Oncol. 2009;93(3):639\u201344. doi: 10.1016\/j.radonc.2009.09.006 .","journal-title":"Radiother Oncol"},{"issue":"2","key":"1583_CR34","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ijrobp.2009.12.063","volume":"77","author":"MJ Sambade","year":"2010","unstructured":"Sambade MJ, Kimple RJ, Camp JT, Peters E, Livasy CA, Sartor CI, et al. Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like\/EGFR+ breast tumor xenografts. Int J Radiat Oncol Biol Phys. 2010;77(2):575\u201381. doi: 10.1016\/j.ijrobp.2009.12.063 .","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16_suppl","key":"1583_CR35","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1200\/jco.2005.23.16_suppl.3583","volume":"23","author":"ALA Fields","year":"2005","unstructured":"Fields ALA, Rinaldi DA, Henderson CA, Germond CJ, Chu L, Brill KJ, et al. An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer. J Clin Oncol (Meeting Abstracts). 2005;23(16_suppl):3583.","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"24","key":"1583_CR36","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1200\/JCO.2007.11.1765","volume":"25","author":"QS Chu","year":"2007","unstructured":"Chu QS, Schwartz G, de Bono J, Smith DA, Koch KM, Versola MJ, et al. Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. J Clin Oncol. 2007;25(24):3753\u20138. doi: 10.1200\/JCO.2007.11.1765 .","journal-title":"J Clin Oncol"},{"issue":"12","key":"1583_CR37","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1093\/annonc\/mdm366","volume":"18","author":"RS Midgley","year":"2007","unstructured":"Midgley RS, Kerr DJ, Flaherty KT, Stevenson JP, Pratap SE, Koch KM, et al. A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Ann Oncol. 2007;18(12):2025\u20139. doi: 10.1093\/annonc\/mdm366 .","journal-title":"Ann Oncol"},{"issue":"15 Pt 1","key":"1583_CR38","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1158\/1078-0432.CCR-07-0004","volume":"13","author":"WS Siegel-Lakhai","year":"2007","unstructured":"Siegel-Lakhai WS, Beijnen JH, Vervenne WL, Boot H, Keessen M, Versola M, et al. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin\/fluorouracil\/leucovorin (FOLFOX4) in patients with solid tumors. Clin Cancer Res. 2007;13(15 Pt 1):4495\u2013502. doi: 10.1158\/1078-0432.CCR-07-0004 .","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1583_CR39","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"JY Douillard","year":"2013","unstructured":"Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023\u201334. doi: 10.1056\/NEJMoa1305275 .","journal-title":"N Engl J Med"},{"key":"1583_CR40","volume-title":"AJCC cancer staging manual","author":"SB Edge","year":"2010","unstructured":"Edge SB, American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.","edition":"7"},{"issue":"976","key":"1583_CR41","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1259\/bjr\/57848689","volume":"82","author":"M Drzymala","year":"2009","unstructured":"Drzymala M, Hawkins MA, Henrys AJ, Bedford J, Norman A, Tait DM. The effect of treatment position, prone or supine, on dose-volume histograms for pelvic radiotherapy in patients with rectal cancer. Br J Radiol. 2009;82(976):321\u20137. doi: 10.1259\/bjr\/57848689 .","journal-title":"Br J Radiol"},{"issue":"6-7","key":"1583_CR42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.canrad.2011.07.236","volume":"15","author":"JF Bosset","year":"2011","unstructured":"Bosset JF, Servagi-Vernat S, Crehange G, Azria D, Gerard JP, Hennequin C. Rectal cancer: the radiation basis of radiotherapy, target volume. Cancer Radiother. 2011;15(6-7):431\u20135. doi: 10.1016\/j.canrad.2011.07.236 .","journal-title":"Cancer Radiother"},{"issue":"3","key":"1583_CR43","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ijrobp.2008.08.070","volume":"74","author":"RJ Myerson","year":"2009","unstructured":"Myerson RJ, Garofalo MC, El Naqa I, Abrams RA, Apte A, Bosch WR, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys. 2009;74(3):824\u201330. doi: 10.1016\/j.ijrobp.2008.08.070 .","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1583_CR44","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.ijrobp.2006.02.050","volume":"65","author":"S Roels","year":"2006","unstructured":"Roels S, Duthoy W, Haustermans K, Penninckx F, Vandecaveye V, Boterberg T, et al. Definition and delineation of the clinical target volume for rectal cancer. Int J Radiat Oncol Biol Phys. 2006;65(4):1129\u201342. doi: 10.1016\/j.ijrobp.2006.02.050 .","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 Suppl","key":"1583_CR45","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1016\/j.ijrobp.2009.05.071","volume":"76","author":"BD Kavanagh","year":"2010","unstructured":"Kavanagh BD, Pan CC, Dawson LA, Das SK, Li XA, Ten Haken RK, et al. Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S101\u20137. doi: 10.1016\/j.ijrobp.2009.05.071 .","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1583_CR46","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1118\/1.2426403","volume":"34","author":"AC Spalding","year":"2007","unstructured":"Spalding AC, Jee KW, Vineberg K, Jablonowski M, Fraass BA, Pan CC, et al. Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions. Med Phys. 2007;34(2):521\u20139.","journal-title":"Med Phys"},{"issue":"3 Suppl","key":"1583_CR47","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.1016\/j.ijrobp.2009.02.090","volume":"76","author":"AN Viswanathan","year":"2010","unstructured":"Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU. Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S116\u201322. doi: 10.1016\/j.ijrobp.2009.02.090 .","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1583_CR48","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1201\/b13224-10","volume-title":"Basic clinical radiobiology","author":"SM Bentzen","year":"2009","unstructured":"Bentzen SM, Joiner MC. The linear-quadratic approach in clinical practice. In: Joiner M, van der Kogel A, editors. Basic clinical radiobiology. 4th ed. London: Hodder Arnold; 2009. p. 120\u201334.","edition":"4"},{"issue":"2","key":"1583_CR49","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.radonc.2009.06.027","volume":"92","author":"V Valentini","year":"2009","unstructured":"Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM, et al. Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol. 2009;92(2):148\u201363. doi: 10.1016\/j.radonc.2009.06.027 .","journal-title":"Radiother Oncol"},{"issue":"1","key":"1583_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nrd1927","volume":"5","author":"DA Berry","year":"2006","unstructured":"Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006;5(1):27\u201336. doi: 10.1038\/nrd1927 .","journal-title":"Nat Rev Drug Discov"},{"key":"1583_CR51","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/1740774508089279","volume":"5","author":"JJ Lee","year":"2008","unstructured":"Lee JJ, Liu DD. A predictive probability design for phase II cancer clinical trials. Clin Trials. 2008;5:93\u2013106. doi: 10.1177\/1740774508089279 .","journal-title":"Clin Trials"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-016-1583-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T19:20:22Z","timestamp":1498332022000},"score":1,"resource":{"primary":{"URL":"http:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-016-1583-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,21]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1583"],"URL":"https:\/\/doi.org\/10.1186\/s13063-016-1583-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,21]]},"article-number":"459"}}